Nebula Research & Development LLC Erasca, Inc. Transaction History
Nebula Research & Development LLC
- $852 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding ERAS
# of Institutions
152Shares Held
226MCall Options Held
10.9KPut Options Held
65.1K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$28.9 Million2.92% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.7MShares$24.9 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$24.2 Million6.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$18.9 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA12.5MShares$18.6 Million4.12% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $182M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...